Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Mission Bio completes $70M Series C for its tech to enable better cancer treatments

By Tom Salemi | August 13, 2020

Mission BioMission Bio has secured $70 million in Series C financing to scale its single-cell multi-omics technology, according to the company.

Novo Growth, the growth equity of Novo Holdings, led the round that included new investor Soleus Capital. Previous investors Mayfield, Cota, and Agilent also participated in the financing, which brings the company’s total funding to more than $120 million.

The South San Francisco-based startup says the funds will be used to expand its reach in more effective clinical trials for novel cancer treatments, as well as characterization for cell and gene therapy.

“We are on a mission to help our customers eliminate cancer,” said Charlie Silver, CEO, and Co-founder of Mission Bio. “With access to multiple layers of the cellular profile, the Tapestri Platform can help identify novel biomarkers in diseased cells, monitor therapy resistance and response, and accelerate novel therapies through clinical trials. We are delighted to partner with Novo Holdings to advance our impact in drug development and cell and gene therapy.”

According to the release, Mission Bio’s Tapestri Platform is the first-ever single-cell multi0omics platform capable of detecting DNA and protein changes simultaneously from the same cell. The company says it’s able to detect DNA and protein changes simultaneously, which allows to develop more impactful precision therapies.

As part of the financing, Robert Ghenchev, senior partner and head of Novo Growth, has joined Mission Bio’s board of directors. “In Novo Growth, our strategy is to support companies developing cutting edge science that has significant potential to positively impact patients and society,” Ghenchev said in the release. “Single-cell analysis has proven highly valuable in cancer research, and we are confident the technology will be used increasingly to unlock key insights into blood cancers, as well as solid tumor indications.”

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Psilocybin mushrooms
Psilocybin narrowly beat Lexapro in small depression study
Bristol Myers Squibb
FDA approves Bristol-Myers Squibb immunotherapy for gastric cancer
Thermo Fisher PPD
Thermo Fisher to buy PPD for $17B
COVID-19 therapies vaccines coronavirus
EU won’t renew J&J, AstraZeneca vaccine contracts, report says

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards